Pharmatech and Cure Forward to Accelerate Oncology Clinical Trial Enrollment

New collaboration to connect more patients to relevant clinical

trials to accelerate approval of new cancer therapies

Pharmatech, Inc., with its large network of research-oriented oncology

practices, announced today a new collaboration with Cure Forward, a

patient activation company. Pharmatech will access Cure Forward s large

network of cancer patients to identify clinical study candidates.

Through the collaboration, the two companies aim to make clinical trials

more accessible in community healthcare settings and support

faster approval of targeted therapies for cancer patients.

This Smart News Release features multimedia. View the full release here:

http://www.businesswire.com/news/home/20151001006487/en/

According to an Institute of Medicine study in 2010, 85% of oncology

patients are unaware that trials are an option to consider. Cure Forward

disrupts conventional patient education resources and trial-recruiting

approaches by providing a streamlined portal at the point of care for

Pharmatech s broad network of community oncology providers,enabling

Pharmatech to target recruitment for clinically relevant cancer therapy

trials to patients who meet enrollment criteria, but otherwise have more

limited awareness of trials than patients connected to comprehensive

academic medical centers.

Through Cure Forward s website, patients can retrieve diagnostic test

results ordered by their physicians from accredited clinical laboratory

test providers, and then use that data to access educational

information, collaborate with other patients, and enable their

de-identified data to support more precise and real-time investigation

of available treatment options, including invitations to participate in

relevant clinical trials. Pharmatech has developed the unique capability

to establish clinical trial sites in as few as 10 days at the point of

care in communities.

Clinical trial recruiters have long struggled to identify sufficient

numbers of patients that meet enrollment criteria, and this divide has

become more challenging with the increased development of targeted

oncology therapies, said Rob Bohacs, CEO of Pharmatech. We recognize

the broad value of making trials more visible and available to eligible

patients, wherever they are. Accessing Cure Forward s patient community

complements our innovative site deployment capabilities, so that our

investigators can enroll eligible participants and complete their

studies.

With its unique clinical trial matchmaking technology, Cure Forward

inverts conventional approaches to trial recruitment by bringing trial

invitations directly to patients. The Clinical Trial Exchange is Cure

Forward s first revenue-generating line of business, drawn from fees

charged to trial recruiters. Following an initial collaboration phase

during which Pharmatech and Cure Forward will optimize the Clinical

Trial Exchange system, Pharmatech will become a commercial user of the

platform as a recruitment tool for its advanced clinical trials.

At Cure Forward, we believe that every patient deserves to access to

cutting-edge therapies through clinical trials. Our partnership with

Pharmatech will create more opportunities for the patients who access

the Cure Forward platform to accelerate clinical development, so that

new targeted therapies get to the right patients more quickly, said

Martin Naley, CEO of Cure Forward.

About Cure Forward

Cure Forward is built on the desire to help patients identify and better

understand relevant treatment options for their condition by bridging

the gap for patients and precision medicine, beginning in cancer.

Through our website, patients can become champions of their own care,

work more effectively with care providers and make more informed choices

toward the best treatment paths. As a multisided platform, the company

overcomes inefficiencies that currently separate patients from the

insights and options that can shape their care and support their

treatment journey. Cure Forward solves critical business needs for its

diagnostic laboratory, health care provider, and clinical trial

partners, including the potential to fill trials more quickly through

its unique clinical trial exchange. Cure Forward is based in Cambridge,

Massachusetts and was incubated and launched by Apple Tree Partners, a

leading healthcare venture capital firm headquartered in New York City.

About Pharmatech Oncology

Pharmatech, Inc. is an oncology Contract Research Organization (CRO)

that accelerates the drug development process by solving the most

critical challenge facing oncology clinical trials site activate and

enrollment timelines. Through an organized network of cancer clinics,

the company focuses on advancing the development of products for a broad

range of pharmaceutical and biotechnology companies, and on promoting

the inclusion of clinical trials in the spectrum of patient treatment

options.

View source version on businesswire.com: http://www.businesswire.com/news/home/20151001006487/en/

Media:

For Cure Forward:

Coltrin Associates

Jennifer

Webb, 212-221-1616

Jennifer_webb@coltrin.com

Copyright Business Wire 2015Business WireOctober 1, 2015 - 12:17 PM EDTNews by QuoteMediawww.quotemedia.com

关注同花顺财经（ths518），获取更多机会